|
|
|
|
|
|
|
|
Welcome to the HCV Advocate’s AASLD Conference coverage. In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference. While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted. The other abstracts posted to the web site are HCV related abstracts posted to www.aasld.org that we have not been able to report on or update.
To locate specific abstracts on this page, click on “Edit” at the top of your browser (Microsoft Internet Explorer) and then on Find (on this page). In Netscape, click on “Search” and then on “Find in This Page.” Simply type in a word or term and the search engine will list the related abstracts.
Please click here to view our fact sheet on reading and understanding an abstract.
Thank You,
Alan Franciscus
Editor-in-Chief
Hepatitis C
Drugs in Development
Studies on the new therapies being investigated to treatment hepatitis C that have been studied in humans, but have not been approved by the FDA.
· Albuferon
o
A PHASE 2 STUDY OF ALBUFERON IN
COMBINATION WITH RIBAVIRIN INNON-RESPONDERS TO PRIOR INTERFERON THERAPY FOR
CHRONIC HEPATITIS C. (updated November 16, 2005)
· Amantadine
o DOES AMANTADINE IMPROVE THE VIROLOGICAL SUSTAINED RESPONSE OF NAÏVE PATIENTS WITH CHRONIC HEPATITIS C IN ASSOCIATION WITH PEG-INTERFERON-RIBAVIRIN COMBINATION ? A PROSPECTIVE, RANDOMISED, MULTICENTER, DOUBLE-BLIND STUDY:PRELIMINARY RESULTS IN 200 PATIENTS. (updated November 26, 2005)
· CPG 10101
o IMMUNOPHENOTYPING PROFILE OF CPG 10101, A NEW TLR9 AGONIST ANTIVIRAL FOR HEPATITIS C.
·
GNS 037
o ENTRY INHIBITOR GNS 037 EXHIBITS
POTENT ANTI-HCV ACTIVITY IN VITRO
·
Gamma Interferon
o ANALYSIS OF RESPONSES TO ALPHA AND GAMMA INTERFERONS IN HEPATITIS C VIRUS INFECTED CHIMPANZEES.
o CONSENSUS INTERFERON IN COMBINATION WITH GAMMA INTERFERON AND/OR RIBAVIRIN LEADS TO A SIGNIFICANT RESPONSE IN TREATMENT-NAIVE HEPATITIS C GENOTYPE 1 PATIENTS. (updated November 28, 2005)
· NM283
o CHARACTERIZATION OF NM283 (VALOPICITABINE) RESISTANCE PROFILE USING BOVINE VIRAL DIARRHEA VIRUS.
o ABSENCE OF EFFECT OF PEGYLATED INTERFERON ALFA-2B ON THE PHARMACOKINETICS OF VALOPICITABINE (NM283) IN PATIENTS WITH CHRONIC HEPATITIS C. (updated November 14, 2005)
o RANDOMIZED TRIAL OF VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, VS. RETREATMENT WITH PEG-INTERFERON PLUS RIBAVIRIN (PEGIFN/RBV) IN HEPATITIS C PATIENTS WITH PREVIOUS NON-RESPONSE TO PEGIFN/RBV: FIRST INTERIM RESULTS. (updated November 18, 2005)
· R1479
o HIGH SELECTIVITY AND LOW CYTOTOXICITY ASSOCIATED WITH R1479, A NOVEL INHIBITOR OF HCV REPLICATION.
· SCH 503034
o ANTI-VIRAL ACTIVITY OF SCH 503034, A HCV PROTEASE INHIBITOR, ADMINISTERED AS MONOTHERAPY IN HEPATITIS C GENOTYPE-1 (HCV-1) PATIENTS REFRACTORY TO PEGYLATED INTERFERON (PEG-IFN-Á). (updated November 18, 2005)
o COMBINATION THERAPY WITH
THE HCV PROTEASE INHIBITOR, SCH 503034, PLUS PEG-INTRON INHEPATITIS C
GENOTYPE-1 PEG-INTRON NON-RESPONDERS: PHASE IB RESULTS. (updated November 18, 2005)
· VX-950
o ITMN A AND B, NOVEL INHIBITORS OF THE HCV NS3/4 PROTEASE RETAIN THEIR POTENCY AGAINST VX-950 AND BILN-2016 RESISTANT NS3/4 PROTEASE MUTANTS AND AN IFN-A-2A RESISTANT HCV REPLICON. (updated November 14, 2005)
o FINAL RESULTS OF A PHASE 1B, MULTIPLE-DOSE STUDY OF VX-950, A HEPATITIS C VIRUS PROTEASE INHIBITOR. (updated November 17, 2005)
o PHARMACOKINETICS OF VX-950, AND ITS EFFECT ON HEPATITIS C VIRAL DYNAMIC (updated November 17, 2005)
Drugs
in Development – Preclinical
Drugs that
are being designed and tested to treat hepatitis C, but have not been studied
in humans.
· THERAPEUTIC
VACCINATION FOR CHRONIC HEPATITIS C VIRUS INFECTION IN HCV TRIMERA MICE
· PHARMACOKINETICS,
SAFETY, AND TOLERABILITY OF THE ISATORIBINE ORAL PRODRUG ANA975 IN APHASE 1
HEALTHY VOLUNTEER STUDY. (updated November 28, 2005)
· CANNABINOIDS
BLOCK INTERFERON-MEDIATED SUPPRESSION OF HEPATITIS C VIRUS (HCV) REPLICATION.
(updated
November 14, 2005)
· THE
IMMUNOMODULATOR AS101 INHIBITS HCV REPLICATION. (updated November 14, 2005)
· AN
Á-GLUCOSIDASE INHIBITOR APPROVED FOR USE IN TYPE II DIABETES HAS ANTIVIRAL
ACTIVITY AND DISPLAYS SYNERGY WITH IFN ALFACON-1 IN A SURROGATE SYSTEM FOR HCV. (updated November 22, 2005)
· TREATMENT OF HCV-ASSOCIATED PROGRESSIVE LIVER DISEASE WITH TACROLIMUS: TRIAL USING A MOUSE MODEL.’ (updated November 14, 2005)
Drugs
in Development – Phase 3, 4 Trials
Drugs that have been FDA approved to treat
hepatitis C and have undergone additional testing in special populations and
circumstances.
· SHORT-TERM TREATMENT DURATION FOR HCV-2 AND HCV-3 INFECTED PATIENTS WITH CHRONIC HEPATITIS. (updated November 28, 2005
· FIBROSIS STAGE IS NOT A PREDETERMINANT OF SIGNIFICANT ADVERSE EVENTS IN PREVIOUS INTERFERON (IFN)-RIBAVIRIN (RIBA) TREATMENT FAILURES RECEIVING PEG-INTERFERON-ALFA 2B/RIBA WEIGHT BASED DOSING: RESULTS FROM THE EPIC3 PROGRAM. (updated November 28, 2005
·
MINIMAL IMPORTANT
DIFFERENCE (MID) IN VITALITY SCORE; A NEW OUTCOME MEASURE IN HCV TREATMENT
TRIALS.
·
INTERIM ANALYSIS OF THE SAFETY
AND EFFICACY OF PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN CHRONIC HEPATITIS C
PATIENTS UNABLE TO TOLERATE OR NONRESPONSIVE TO TREATMENT WITH PEGINTERFERON
ALFA-2B PLUS RIBAVIRIN (updated November 21,
2005)
·
WEIGHT-BASED
RIBAVIRIN DOSING (WBD) INCREASES SUSTAINED VIRAL RESPONSE (SVR) INPATIENTS WITH
CHRONIC HEPATITIS C (CHC): FINAL RESULTS OF THE WIN-R STUDY, A US COMMUNITY
BASED TRIAL. (updated November 21, 2005)
HCV
Medications Approved by the FDA
Studies
about the medications approved or indicated to treat hepatitis C. In addition, issues such as retreatment,
refining treatment issues, and treatment in special populations are listed in
this section.
· Infergen (consensus interferon)
o ANTIVIRAL RESPONSE OF HCV GENOTYPE-1 TO CONSENSUS INTERFERON AND RIBAVIRIN COMPARED WITH PEGYLATED INTERFERON AND RIBAVIRIN. (updated November 22, 2005
· Pegasys (peginterferon alfa-2a)
o SUSTAINED VIROLOGICAL RESPONSE (SVR) IS DURABLE AFTER TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) ALONE OR IN COMBINATION WITH RIBAVIRIN (COPEGUS®): RESULTS OF AN ONGOING LONG-TERM FOLLOW-UP STUDY. (updated November 16, 2005)
o ASSOCIATION BETWEEN SUSTAINED VIROLOGICAL RESPONSE (SVR) AND ALT LEVELS IN HIV-HCV CO-INFECTED PATIENTS WHO RECEIVED PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN THE AIDS PEGASYS RIBAVIRIN INTERNATIONAL CO-INFECTION TRIAL (APRICOT). (updated November 26, 2005)
o INTERIM SAFETY ANALYSIS OF PATIENTS ENROLLED IN THE RANDOMIZED, INTERNATIONAL RETREATMENT WITH PEGASYS® IN PATIENTS NOT RESPONDING TO PRIOR PEGINTERFERON ALFA-2B/RIBAVIRIN (RBV) COMBINATION THERAPY (REPEAT) STUDY. (updated November 28, 2005)
o PHARMACOKINETICS AND RESPONSE OF OBESE PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH DIFFERENT DOSES OF PEG-IFN ALPHA2A(40KD) (PEGASYS®). (updated November 26, 2005)
o VIRAL AND METABOLIC FACTORS INFLUENCING ALANINE AMINOTRANSFERASE (ALT) ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C RECEIVING PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN RANDOMIZED PHASE III TRIALS. (updated November 26, 2005)
o IMPACT OF BASELINE HEPATITIS C VIRUS (HCV) RNA AND GENOTYPE ON THE EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN PATIENTS WITH COMPENSATED CIRRHOSIS/BRIDGING FIBROSIS. (updated November 17, 2005)
o FASTING TRIGLYCERIDE LEVELS BEFORE, DURING AND AFTER TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) IN PATIENTS INFECTED WITH HCV GENOTYPE 2 OR 3: THE ACCELERATE SERUM TRIGLYCERIDE SUBSTUDY. (updated November 21, 2005)
o CLUSTERING OF POOR PROGNOSTIC FACTORS IN HEAVIER PATIENTS WITH CHRONIC HEPATITIS C (CHC): BASELINE CHARACTERISTICS AND OUTCOMES WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) IN RANDOMIZED, INTERNATIONAL, PHASE III TRIALS. (updated November 15, 2005)
o PREDICTED OUTCOMES IN PATIENTS WITH PERSISTENTLY ‘NORMAL’ ALT LEVELS AND HCV GENOTYPE 1 TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) 1000/1200 MG/DAY FOR 48 WEEKS. (updated November 17, 2005)
o EFFICACY OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C IN GERMANY – A CONTRIBUTION TO HEALTH CARE RESEARCH. (updated November 18, 2005)
o WEEK 4 VIROLOGICAL RESPONSE WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) PORTENDS A SUSTAINED VIROLOGICAL RESPONSE (SVR) AFTER 24 WEEKS IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS WITH PERSISTENTLY ‘NORMAL’ ALT ACTIVITY. (updated November 26, 2005)
o AN EVALUATION OF THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) FOR THE FIRST TREATMENT OF MILD CHRONIC HEPATITIS C (CHC). (updated November 26, 2005)
o RAPID VIROLOGICAL RESPONSE AT WEEK 4 (RVR) OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN (RBV, COPEGUS®) TREATMENT PREDICTS SUSTAINED VIROLOGICAL RESPONSE (SVR) AFTER 24 WEEKS IN GENOTYPE 1 PATIENTS. (updated November 15, 2005)
· Peg-Intron (peginterferon alfa-2b)
o PEGINTERFERON A-2B 1 MCG/KG DOSE PLUS RIBAVIRIN 800-1200MG FOR 24-48 WEEKS, ACCORDING TO GENOTYPE, IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C: EFFICACY AND COST-EFFECTIVENESS EVALUATION. (updated November 15, 2005)
o TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PEGINTERFERON ALFA-2B (PEGIFN), HIGH WEIGHT BASED DOSE RIBAVIRIN (RVN) AND EPOETIN ALFA (EPO) ENHANCES SUSTAINED VIROLOGIC RESPONSE (SVR). (updated November 26, 2005)
o PEGINTERFERON A-2B 1 MCG/KG DOSE PLUS RIBAVIRIN 800-1200MG FOR 24-48 WEEKS, ACCORDINGTO GENOTYPE, IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C: EFFICACY AND COST-EFFECTIVENESS EVALUATION. (updated November 26, 2005)
o
INTERFERON (IFN)
INDUCED THROMBOCYTOPENIA IS INDEPENDENT OF LEVEL OF FIBROSIS IN PATIENTS WITH
CHRONIC HEPATITIS C (CHC): RESULTS FROM THE EPIC3 PROGRAM. (updated November 28, 2005)
o PEGETRON PROSPECTIVE OPTIMAL WEIGHT-BASED DOSING RESPONSE PROGRAM (POWER): PRELIMINARY RESULTS. (updated November 28, 2005)
·
Ribavirin
o EVIDENCE OF SATURABLE RIBAVIRIN ABSORPTION.
Treatment
Issues
Other
treatment related issues such as side effect management, the use of adjunct or
supportive therapies, predictors of treatment response and so forth
· General
o PRIMARY CARE BASED HEPATITIS C TREATMENT: COLLABORATING TO IMPROVE ACCESS, ADHERENCE AND OUTCOMES.
o EXPECTANT MANAGEMENT OF CHRONIC HEPATITIS C INFECTION – THE PATIENT PERSPECTIVE.
o ANTIVIRAL THERAPY IN PATIENTS WITH OCCULT HCV INFECTION.
· African-Americans
o PERSISTENCE WITH HEPATITIS C THERAPY IN AFRICAN AMERICANS AND PATIENTS WITH DEPRESSION IN THE DEPARTMENT OF VETERANS AFFAIRS (VA). (updated November 21, 2005)
o COMPARISON OF AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENT SUSTAINED VIROLOGICRESPONSE IN PEG-IFN ALPHA 2 + WEIGHT-BASED RIBAVIRIN NONRESPONDERS RETREATED WITH IFN ALFACON-1 + IFN GAMMA-1B. (updated November 21, 2005)
· Cirrhosis
o VIRAL FACTORS INFLUENCE SVR IN PTS WITH HCV-RELATED BRIDGING FIBROSIS BUT NOT CIRRHOSIS.
o PEG-INTERFERON ± RIBAVIRIN IN ADVANCED HCV CIRRHOSIS.
o SAFE USE OF PEG-IFN AND RIBAVIRIN IN HCV-CIRRHOTIC PATIENTS UNDERGOING PARTIAL SPLENIC EMBOLIZATION.
· Genotype
· IDU
o DIRECTLY OBSERVED THERAPY (DOT) FOR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION IN INJECTION DRUG USERS (IDUS) – AN INTERIM ANALYSIS. (updated November 15, 2005)
·
Steatosis
· Transplant
o PATIENT SURVIVAL AND FIBROSIS PROGRESSION AFTER LIVER RETRANSPLANTATION FOR HEPATITIS CoINFECTION. (updated November 14, 2005)
o VIRAL QUASISPECIES AND SEVERITY OF RECURRENT HEPATITIS C.
o PREDICTIVE FACTORS OF EARLY AND SUSTAINED VIRAL RESPONSE IN PATIENTS WITH RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION TREATED WITH COMBINED THERAPY (IFN-ALPHA AND RIBAVIRIN). (updated November 14, 2005)
o LONG TERM RESULTS AFTER THERAPY WITH PEGYLATED INTERFERON ALPHA 2A IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS (updated November 14, 2005)
o ANTIVIRAL THERAPY FOR HCV-1B LIVER TRANSPLANT RECIPIENTS: BETTER RESULTS WITH YOUNGER GRAFTS.
· VA
o DIRECT COSTS OF MEDICAL CARE FOR TREATING HEPATITIS C PATIENTS IN A VETERANS AFFAIRS MEDICAL CENTER.
Diagnosis
and Natural History
Data about
diagnosing HCV including acute infection, special populations, disease
progression in general and in special populations, extra-hepatic
manifestations, and occult infection.
· General
· TREATMENT OUTCOMES TO COMBINATION THERAPY IN PATIENTS WITH HCV GENOTYPE 6.
· PERSISTENCE WITH HEPATITIS C THERAPY IN THE DEPARTMENT OF VETERANS AFFAIRS (VA).
· INSULIN INCREASES HEPATITIS C VIRAL RNA REPLICATION IN CELL CULTURE.
· SPONTANEOUS FIBROSIS REGRESSION IN UNTREATED, NONCIRRHOTIC, PERSISTENTLY VIREMIC IRISH WOMEN WITH CHRONIC HEPATITIS C CONTRACTED INITIALLY FROM IMMUNOGLOBULIN ANTI-D: FINAL REPORT. (updated November 15, 2005)
· SPONTANEOUS HCV CLEARANCE IN PATIENTS FOLLOWED IN A HAEMOPHILA UNIT: EVALUATION OF CELLULAR IMMUNITY AGAINST HCV RECOMBINANT PROTEINS. (updated November 13, 2005)
· HCV RNA QUANTIFICATION OF HCV GENOTYPES 1 TO 5: COMPARISON OF 4 DIFFERENT ASSAYS
· EVIDENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN PATIENTS WITH CHRONIC HEPATITIS C (HCV) INFECTION AND MINIMAL LIVER DISEASE. (updated November 13, 2005)
· IMPACT OF HEPATITIS C VIRUS INFECTION AND OTHER COMORBIDITIES ON SURVIVAL IN PATIENTS ON DIALYSIS. (updated November 13, 2005)
· HCV RNA IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMNCS) OF SUSTAINED VIROLOGICAL RESPONDERS TO INTERFERON BASED THERAPIES: IS IT A RISK FOR RELAPSE? (updated November 13, 2005)
· DO SERUM AUTOANTIBODIES AFFECT THE SEVERITY OF CHRONIC HEPATITIS C.
· THE SOURCE OF HCV DIAGNOSIS AFFECTS THE LONG-TERM COURSE OF CHRONIC HEPATITIS C (CHC).
· PERSISTENCE OF HCV INFECTION IN APPARENTLY HEALTHY ANTI-HCV POSITIVE PATIENTS WITH CONSTANTLY SERUM HCV-RNA NEGATIVE AND NORMAL ALT LEVELS. (updated November 13, 2005)
· CRYOGLOBULINEMIA IS ASSOCIATED WITH STEATOSIS AND FIBROSIS IN CHRONIC HEPATITIS C. (updated November 13, 2005)
· CASP7 GENE POLIMORPHISMS AND FIBROSIS PROGRESSION IN CHRONIC HEPATITIS C.
· MONITORING LIVER STIFFNESS: A NEW TOOL TO MEASURE LIVER FIBROSIS DURING THERAPY.
· LIVER HISTOLOGY IN HEPATITIS C PATIENTS WITH NORMAL ALT LEVELS. (updated November 13, 2005)
· OCCULT HCV INFECTION IN HEMODIALYSIS PATIENTS. (updated November 13, 2005)
· SYSTEMATIC REVIEW OF LENGTH AND NUMBER OF PORTAL TRACTS OBTAINED WITH PERCUTANEOUS LIVER BIOPSY. (updated November 13, 2005)
· TRANSJUGULAR LIVER BIOPSY: HOW GOOD IS IT FOR ACCURATE HISTOLOGICAL INTERPRETATION?.
· PROSPECTIVE ANALYSIS OF DISCORDANCE BETWEEN FIBROSCAN AND FIBROTEST WHEN USED IN COMBINATION AS FIRST-LINE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C. (updated November 13, 2005)
· GREATER PREVALENCE OF CIRRHOSIS IN HISPANICS THAN IN CAUCASIANS OR AFRICAN AMERICANS. (updated November 14, 2005)
· INTERNAL MEDICINE RESIDENTS KNOWLEDGE AND MANAGEMENT OF HEPATITIS C VIRUS (HCV) INFECTION IMPROVE WITH A TARGETED EDUCATIONAL INTERVENTION. (updated November 13, 2005)
· HISPANIC RACE/ETHNICITY IS ASSOCIATED WITH AN AGGRESSIVE COURSE OF CHRONIC HEPATITIS C INFECTION: ROLE OF PATIENT DEMOGRAPHICS, HEPATIC STEATOSIS AND NECROINFLAMMATION. (updated November 13, 2005)
· IS LIVER BIOPSY JUSTIFIED IN HEPATITIS C GENOTYPE 2 AND 3? (updated November 13, 2005)
· IMPACT OF CAFFEINE CONSUMPTION ON SERUM ALANINE AMINOTRANSFERASE LEVEL AND HISTOLOGICAL ACTIVITY IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS C. (updated November 13, 2005)
· HEPATITIS C VIRUS(HCV) GENOTYPE AND SUBTYPE DETERMINATION USING A NEW NS5B SEQUENCING TOOL.
· CUTANEOUS SIGNS OF LIVER DISEASE: VALUE FOR PROGNOSIS OF SEVERE FIBROSIS AND CIRRHOSIS. (updated November 13, 2005)
· THE NATURAL HISTORY OF HEPATITIS C VIRUS (HCV) RECURRENCE IN PEDIATRIC LIVER TRANSPLANT
· ACUTE HEPATITIS C: CLINICAL PRESENTATION, LABORATORY FINDINGS, AND TREATMENT OUTCOMES.
· HCV TREATMENT PATTERNS AND UTILIZATION FOR HCV MONO-INFECTED AND HCV/HIV COINFECTED PATIENTS IN THE VETERANS ADMINISTRATION. (updated November 13, 2005)
· BEHAVIOUR OF SUSTAINED RESPONDERS TO ANTI-HCV TREATMENT: MAY HCV INFECTION BE ERADICATED?
· HEPATITIS C TREATMENT RESULTS IN AN ALASKA NATIVE / AMERICAN INDIAN POPULATION.
· Cancer
o TREATMENT OF CHRONIC HEPATITIS C VIRUS IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS
o LONG-TERM OUTCOME OF PATIENTS WITH HCV-RELATED, CHILD' S CLASS A CIRRHOSIS TREATED WITH INTERFERON–ALPHA (IFN): THE IMPACT OF SUSTAINED VIROLOGIC RESPONSE (SVR) ON HEPATOCELLULAR CARCINOMA (HCC) OCCURENCE AND MORTALITY. (updated November 21, 2005)
o BODY MASS INDEX INFLUENCES HEPATIC FUNCTION AND SURVIVAL PROGNOSIS IN PATIENTS WITH HCV-RELATED HEPATOCELLULAR CARCINOMA. (updated November 21, 2005)
· IDU
o NATURAL HISTORY OF HEPATITIS C VIRUS INFECTION AMONG INJECTION USERS IN VANCOUVER, CANADA.
· Psychiatric
Issues
o COMBINATION THERAPY USING PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH PSYCHIATRIC ILLNESSES.
Diagnostic Tools
Information
about various diagnostic tools used to treat and manage hepatitis C including
liver biopsy, and non-invasive tests that measure liver health and disease.
- EARLY AND COST EFFECTIVE PREDICTION OF TREATMENT OUTCOME WITH IFNA2B OR PEG-IFNA2B PLUS RIBAVIRIN COMPUTING INFECTED CELLS DYNAMICS BY ALT AND HCV-RNA DECLINE DURING THE FIRST MONTH.
- EFFECT OF ANGIOTENSIN II TYPE1 RECEPTOR ANTAGONIST ON INSULIN RESISTANCE AND LIVER FIBROSIS OF CHRONIC HEPATITIS C PATIENTS.
- REPEATED LIVER STIFFNESS MEASUREMENT USING FIBROSCAN® FOR THE FOLLOW-UP OF UNTREATED HCV PATIENTS AND FOR THE EVALUATION AND MONITORING OF HISTOLOGICAL RESPONSE IN HCV RESPONDERS: A PROSPECTIVE LONGITUDINAL STUDY.
- THE USEFULNESS OF ELASTOMETRY USING FIBROSCAN502 FOR ASSESSMENT OF LIVER FIBROSIS STAGE IN CHRONIC HEPATITIS C.
- IDENTIFYING A SUBSET OF PATIENTS WHO DO NOT WARRANT PRETREATMENT LIVER BIOPSY FOR HEPATITIS C (HCV).
- UTILITY OF TMA TESTING DURING ANTIVIRAL TREATMENT OF ADVANCED HEPATITIS C
·
Liver Imaging
Modalities / Public Policy, Epidemiology, and Decision
Analysis
o
VALIDATION
OF AN MRI TECHNIQUE TO MEASURE LIVER FAT CONTENT. (updated Nov 12, 2005)
o AMOUNT AND TYPE OF LIVER FIBROSIS
DETECTED BY STIFFNESS MEASUREMENTS.
o PREVALENCE AND FACTORS ASSOCIATED WITH
FAILURE OF LIVER STIFFNESS MEASUREMENT USING FIBROSCAN® IN A PROSPECTIVE STUDY
OF 2114 EXAMINATIONS. (updated Nov 12, 2005)
o NON-INVASIVE DETECTION OF CELLULAR
PROLIFERATION IN THE WOODCHUCK MODEL OF HEPATOCELLULAR CARCINOMA.
o ADMINISTRATION OF ERYTHROPOIETIN FOR
HEPATITIS C TREATMENT-RELATED ANEMIA IS NOT COST EFFECTIVE. (updated Nov 12, 2005)
o HIV TESTING AND HIV SEROPOSITIVITY AMONG
PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: MISSED OPPORTUNITIES FOR
EARLY DIAGNOSIS. (updated Nov 12, 2005)
o COFFEE DRINKING DECREASES THE RISK OF
CHRONIC LIVER DISEASE IN THE UNITED STATES POPULATION. (updated Nov 12, 2005)
o THE COST OF VARICEAL BLEEDING IN CIRRHOSIS
- A COMPARISON OF A DECISION BASED ECONOMIC MODEL AND PATIENT DATA. (updated Nov 12, 2005)
o IMPACT OF PATIENT RACE AND GENDER ON
THE CARE OF A LARGE COHORT OF COMMUNITY BASED HEPATITIS C PATIENTS. (updated Nov 12, 2005)
o COST-EFFECTIVENESS OF TREATMENT FOR
CHRONIC HEPATITIS C INFECTION IN PATIENTS COINFECTED WITH HUMAN
IMMUNODEFICIENCY VIRUS (updated Nov 12, 2005)
o TREATMENT ALTERNATIVES FOR HEPATITIS B
CIRRHOSIS: A COST-EFFECTIVENESS ANALYSIS.
o THE ROLE OF LIVER BIOPSY FOR
ASYMPTOMATIC LIVER ENZYME ELEVATION. (updated Nov 12, 2005)
o PSYCHOSOCIAL FACTORS IN LIVER
TRANSPLANTATION: HOW ARE U.S. CENTERS EVALUATING THEM. (updated Nov 12, 2005)
o REAL TIME ULTRASOUND GUIDED LIVER
BIOPSY IN REAL LIFE; A COMPARISON OF PRE-BIOPSY VERSUS REAL TIME ULTRASOUND.
(updated
Nov 12, 2005)
o INFORM CONSENT FOR CLINICAL TRIALS-
STILL SOME WAY TO GO. (updated Nov 12, 2005)
o METHODOLOGICAL ISSUES IN COST
EFFECTIVENESS EVALUATION OF HEPATITIS A VACCINE: A SYSTEMATIC REVIEW (updated Nov 12, 2005)
o QUALITY-OF-LIFE TRADOFFS FOR HEPATITIS
C TREATMENT: DO PATIENTS AND HEALTH PROFESSIONALS AGREE? (updated Nov 12, 2005)
Epidemiology
Studies that
report HCV prevalence and/or trends in the general population as well as in
special populations or groups.
· CURRENT EPIDEMIOLOGICAL TRENDS AND OUTCOME IN A
LARGE COHORT OF ACUTE HEPATITIS C PATIENTS. (updated
November 13, 2005)
· PREVALENCE OF DIABETES MELLITUS AND INSULIN
RESISTANCE IN JAPANESE PATIENTS WITH CHRONIC HEPATITIS C. (updated November 14, 2005)
· ANALYSIS OF THE HCV GENOTYPE 5A MOLECULAR
EPIDEMIOLOGY IN BELGIUM USING A BAYESIAN APPROACH.
· A SYSTEMATIC REVIEW OF PANELS OF SURROGATE NON-INVASIVE
MARKERS OF LIVER FIBROSIS IN HEPATITIS C. (updated
November 13, 2005)
· OUTBREAK OF HEPATITIS C VIRUS INFECTION DURING
SCLEROTHERAPY OF VARICOSE VEINS: LONG-TERM FOLLOW-UP OF 160 PATIENTS (3775
PATIENT-YEARS). (updated November 13, 2005)
· SEXUAL DYSFUNCTION IS HIGHLY PREVALENT AMONG MEN
WITH CHRONIC HEPATITIS C VIRUS INFECTION AND NEGATIVELY IMPACTS HEALTH-RELATED
QUALITY OF LIFE. (updated November 13, 2005)
· SELF-REPORTED HEPATITIS C VIRUS ANTIBODY STATUS
AND RISK BEHAVIOR IN YOUNG INJECTORS. (updated
November 13, 2005)
· RACIAL DISPARITIES IN HEPATITIS C TESTING.
· PREVALENCE OF RISK FACTORS FOR HCV TRANSMISSION
IN HIV INFECTED AND HIV/HCV CO-INFECTED PATIENTS. (updated November
18, 2005)
· ALCOHOL USE IN US VETERANS: A MULTICENTER STUDY
OF 4,061 HEPATITIS C-INFECTED PATIENTS. (updated
November 13, 2005)
· PREVALENCE AND CHARACTERISTICS OF HEPATITIS C
VIRUS INFECTION IN A POPULATION OF PATIENTS WITH SICKLE CELL DISEASE AT A
TERTIARY CARE TEACHING HOSPITAL (updated
November 13, 2005)
· CHANGING EPIDEMIOLOGY OF HCV AND HBV INFECTIONS
IN NORTHERN ITALY: A SURVEY IN THE GENERAL POPULATION. (updated November 13, 2005)
· DISPARITIES IN THE CLINICAL CHARACTERISTICS,
EVALUATION AND OUTCOMES OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS WITH
HEPATITIS C. (updated November 13, 2005)
· HOW WELL INFORMED ARE HCV-INFECTED GERMAN
SUBJECTS ABOUT THEIR DISEASE AND HOW DO THEY PERCEIVE THE PUBLIC INFORMATION
STATUS ABOUT HEPATITIS C. (updated November 13,
2005)
· HEPATITIS B AND C: PREVALENCE AND SOCIAL FACTORS
ASSOCIATED WITH SERO-POSITIVITY AMONG CHILDREN IN KARACHI, PAKISTAN. (updated November 13, 2005)
· FACTORS ASSOCIATED WITH THE PRESENCE OF
HEPATITIS C (HCV) RNA AMONG ANTI-HCV POSITIVE YOUNG INJECTING DRUG USERS (IDUS)
IN METROPOLITAN CHICAGO. (updated November 13,
2005)
· FIVE MILLION AMERICANS INFECTED WITH THE
HEPATITIS C VIRUS: A CORRECTED ESTIMATE. (updated
November 21, 2005)
· CAUSES OF DEATH IN PEOPLE WITH HEPATITIS B OR C
INFECTION: A POPULATION BASED COHORT STUDY.
· MASS SCREENINGS IN NEW YORK CITY REVEAL HIGH PREVALENCE OF HEPATITIS B IN AN URBAN ASIAN POPULATION.
· COMPARATIVE EPIDEMIOLOGY OF HEPATITIS C AND HEPATITIS B IN MANITOBA, CANADA.
· CAUSES OF DEATH IN PEOPLE WITH HEPATITIS B OR C INFECTION: A POPULATION BASED COHORT STUDY (updated November 21, 2005)
HIV/HCV Coinfection
This section lists all of the studies released at AASLD about HIV/HCV coinfection.
· Diagnosis
o FACTORS ASSOCIATED WITH LIVER
CLINIC REFERRAL OF HEPATITIS C VIRUS (HCV)-INFECTED PATIENTS.
· HCV Treatment
o DOES TYPE
AND DURATION OF ANTIRETROVIRAL THERAPY ATTENUATE LIVER FIBROSIS IN HIV/HCV
COINFECTED PATIENTS? (updated November 13, 2005)
o PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS
INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C IN HIV-COINFECTED
PATIENTS (updated November 16, 2005)
o
· Natural History
o
SEVERE IMPAIRMENT IN QUALITY OF LIFE
IN HIV POSITIVES WITH HEPATITIS C BUT NOT WITH HEPATITIS B.
o HIV INCREASES THE FORMATION AND
ACTIVATION OF MACROPHAGE RESERVOIRS OF HCV IN COINFECTED PATIENTS.
o ANALYSIS OF CD1D-DEPNDENT NKT FUNCTION
IN SUBJECTS WITH HCV VERSUS HIV/HCV INFECTION
o HCV-SPECIFIC T-CELL RESPONSES OF ACUTELY
HCV INFECTED INDIVIDUALS WITH AND WITHOUT HIV